Affordable Access

Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis.

Authors
  • Passam, F H
  • Alexandrakis, M G
  • Moschandrea, J
  • Sfiridaki, A
  • Roussou, P A
  • Siafakas, N M
Type
Published Article
Journal
International Journal of Immunopathology and Pharmacology
Publisher
SAGE Publications
Publication Date
Jan 01, 2006
Volume
19
Issue
1
Pages
161–170
Identifiers
PMID: 16569354
Source
Medline
License
Unknown

Abstract

Increased angiogenic activity has been demonstrated in lymphoproliferative diseases including Hodgkin's disease. In the current study, the levels of circulating angiogenic molecules in 60 Hodgkin's patients were determined prior to and after treatment and correlated to disease stage and prognostic score. Hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were increased in Hodgkin's patients in comparison to healthy controls (p<0.001). Angiogenin and angiopoietin-2 levels did not differ from controls. HGF, VEGF, TNF-alpha and angiogenin decreased significantly in Hodgkin's patients after standard treatment (p<0.001 for HGF, p<0.05 for VEGF, TNF-alpha and angiogenin). Furthermore, HGF and TNF-alpha increased with advancing stage of disease (p<0.05). HGF and VEGF correlated significantly with IL-6 (r=0.56, p<0.0005 and r=0.57, p<0.001 respectively). In conclusion, Hodgkin's disease displays an angiogenic activity as depicted by the increased serum levels of a number of angiogenic cytokines. HGF seems to be the prominent molecule in Hodgkin's disease, which may be used to monitor the disease status and the response to treatment.

Report this publication

Statistics

Seen <100 times